|
|
|
04.08.25 - 14:06
|
Medincell: Notice of the 2025 Annual General Meeting Published (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell's (Paris:MEDCL) combined annual general meeting (ordinary and extraordinary) will be held on September 11, 2025, at 6pm at the Company's headquarters.
The notice was published in the “BALO” (French):
https://www.journal-officiel.gouv.fr/telechargements/BALO/pdf/2025/0804/202508042503963.pdf
The resolutions proposed for voting at the General Assembly include:
Approval of the parent company and consolidated financial statements for the 2024-2025 fiscal year and allocation of the result;
Election of new independent board members, seasoned professionals in the pharmaceutical field: Ms. Sharon Mates, Mr. Charles Kunsch, and Mr. Pascal Touchon;
Approval of existing related-party agreements;
Approval of executive compensation elements, including the budget allocated to Board of Directors' remuneration, which has been revised this year to reflect:
- The transition from a governance structure based on a Supervisory Board and Management Board t...
|
|
|
29.07.25 - 17:48
|
Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL):
Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA®, acquired by Johnson & Johnson for $14.6 billion in April 2025.
Dr. Mates said: "Medincell is entering a new era and I'm excited to help shape its future. Its vision and achievements closely align with my passion for advancing medical innovation and delivering meaningful solutions for patients."
Charles Kunsch, PhD, is a seasoned life sciences executive with over 30 years of experience, including as former Managing Director at AbbVie Ventures, where he led investments in pioneering biotech companies.
Dr. Kunsch said: “Throughout my career, I've seen how innovation and collaboration can transform bold ideas into meaningful impact. These values are deeply rooted at Medincell. They've already taken the company far and laid a strong foundation for a new phase o...
|
|
|
17.06.25 - 17:48
|
Medincell Publishes its Consolidated Annual Financial Results (Business Wire)
|
|
|
(April 1st, 2024 - March 31st, 2025)
Consolidated financial statements for the year 2024-25 (IFRS standards)
Revenues: €25.4 million, multiplied by 2.8x compared to previous year
→ Other income: €2.3 million, bringing total income to €27.7 million
Operating expenses: €38.5 million, a 17% increase compared to previous year
Operating result: €(10.8) million, a 48% year-over-year improvement
Net result: €(18.4) million, a 26% year-over-year improvement
Cash, cash equivalents and low-risk financial investments at the closing: €71.9 million
→ Composed of €59.0 million in cash and cash equivalent and €12.9 million in low-risk financial investments
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL):
Christophe Douat, CEO of Medincell: “2024 marked the beginning of a new era for Medincell with the surge in our revenues notably fueled by the strong performance of UZEDY. Looking ahead, we anticipate further revenue acceleration with the expected 2026 approval and ...
|
|
|
10.06.25 - 18:03
|
Medincell to Present 2024-2025 Annual Results on June 17, 2025 (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentations will be held in both French and English to accommodate a broad audience of investors, analysts, and stakeholders:
French session: 6:00pm CEST / 12:00pm ET
> https://www.medincell.com/fr/live-fr/
English session: 7:00pm CEST / 1:00pm ET
> https://www.medincell.com/live-en/
During each session, Medincell's management team will provide an overview of the company's performance and strategic outlook and will respond to questions from shareholders. Questions may be submitted in advance via email to communication@medincell.com or asked live during the videoconferences.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-...
|
|
|
|
|
19.02.25 - 08:30
|
Medincell Announces Successful c.€43 Million Global Offering (Business Wire)
|
|
|
Success of the operation with €42.9 million raised.
Participation of US and European Healthcare specialist investors, as well as historical shareholders, in the transaction.
Funds raised will enable Medincell to strengthen licensing opportunities by expanding BEPO® technology's reach into new molecules and indications, and by potentially considering complementary technologies. Additionally, funds raised will improve the shareholder structure and reinforce the company's balance sheet, enhancing financial flexibility to drive additional long-term value creation.
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL):
This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or Japan
Medincell, a commercial-stage pharmaceutical technology company developing a portfolio of long-acting injectable products in various therapeutic areas (the "Company"), announced to...
|
|
|
18.02.25 - 18:57
|
Medincell Launches a Global Offering for Approximately 10% of Its Share Capital (Business Wire)
|
|
|
The Global Offering, for approximately 10% of the Company's share capital, is aimed at international institutional investors, via a Private Placement through an accelerated book-building process.
The Global Offering is also aimed at retail investors via PrimaryBid platform, exclusively in France.
Funds raised will enable Medincell to strengthen licensing opportunities by expanding BEPO® technology's reach into new molecules and indications, and potentially by potentially considering complementary technologies. Additionally, funds raised will improve our shareholder structure and reinforce the company's balance sheet, enhancing financial flexibility to drive additional long-term value creation.
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL):
THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY,
INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA
Medincell (Paris:MEDCL), a commercial-stage pharmaceuti...
|
|
|
15.01.25 - 18:03
|
Medincell: Publication of the 2025 Financial Calendar (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL):
Event
Date
Annual results 2024-2025
(April 2024-March 2025)
Tuesday, June 17, 2025
General Meeting
Thursday, September 11, 2025
Half-Year results 2025-2026
(April-September 2025)
Tuesday, December 9, 2025
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, w...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
